3 Key Takeaways from the 2026 J.P. Morgan Healthcare Conference

3 Key Takeaways from the 2026 J.P. Morgan Healthcare Conference

3 Key Takeaways from the 2026 J.P. Morgan Healthcare Conference  

This year’s J.P. Morgan Healthcare Conference in San Francisco made one thing clear: healthcare leaders are navigating uncertainty with discipline, not hesitation. Across announcements, partnerships, and executive conversations, three themes emerged each revealing something important about where capital, confidence, and concern intersect. 

  1. AI Is Moving from Excitement to Infrastructure
    AI dominated the conference narrative, and the enthusiasm is realand backed by significant capital. Investments, such as Nvidia and Eli Lilly’s $1B joint innovation lab and Hippocratic AI’s expansion into life sciences, signal that AI is no longer experimental. Companies are funding AI as core infrastructure across R&D, clinical care, and operations. In a cautious market, AI stands out as one of the few areas where excitement and spending clearly align. 
  2. Capital Is Availablebut Being Deployed Selectively
    Despite global uncertainty, JPM did not reflect a capital shortage. Instead, organizations are sitting on cash and deploying it with greater scrutiny. Large licensing and partnership deals, often tied to late-stage or high-impact assets, suggest confidence in long-term growth, paired with a preference for fewer, higher-conviction investments rather than broad bets. 
  3. Pharma Is Leaning into Partnerships to Manage Risk
    Pharmaceuticalcompanies continue to rely on strategic collaborations to accelerate pipelines and spread risk. Multi-billion-dollar licensing agreements in oncology and neurology underscore urgency around time-to-market, pricing pressure, and innovation efficiency. Even amid geopolitical and regulatory complexity, deal-making remains active when the strategic case is strong.

The Pulse: 

The mood coming out of JPM can best be described as disciplined optimism. Organizations are cautious, but not frozen. Capital is available, but targeted. AI is a clear priority. And while leaders are realistic about risk, they are actively investing in solutions that scale, integrate, and deliver real-world value.